Study on predictors for treatment efficacy of rituximab in patients with PLA2R-negative primary membranous nephropathy
Objective To evaluate the clinical efficacy of rituximab (RTX) in patients with phospholipase A2 receptor (PLA2R)-negative primary membranous nephropathy (PMN) presenting as nephrotic syndrome, and to identify predictors for treatment efficacy. Methods This retrospective cohort study included 19 bio...
Saved in:
| Main Author: | XU Lili, HU Xiaofan, LI Hao, WANG Weiming |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Diagnostics Concepts & Practice
2025-06-01
|
| Series: | Zhenduanxue lilun yu shijian |
| Subjects: | |
| Online Access: | https://www.qk.sjtu.edu.cn/jdcp/fileup/1671-2870/PDF/1756094078939-2131883305.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research progresson correlation of PLA2R1 and HLA gene polymorphisms with susceptibility toidiopathic membranous nephropathy
by: XIE Da-xing, et al.
Published: (2019-01-01) -
PLA2R-associated membranous nephropathy associated with renal clear cell carcinoma: one case report
by: Xu Xiao-chang, et al.
Published: (2021-01-01) -
Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study
by: Xi Cheng, et al.
Published: (2025-08-01) -
Efficacy and safety of rituximab for membranous nephropathy in adults: a meta-analysis of RCT
by: Baike Mao, et al.
Published: (2025-04-01) -
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
by: Maxime Teisseyre, et al.
Published: (2025-03-01)